FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281567257> ?p ?o ?g. }

• W4281567257 endingPage "3040.e5" @default.
• W4281567257 startingPage "3030" @default.
• W4281567257 abstract "The genetic landscape of melanoma resistance to targeted therapy with small molecules inhibiting BRAF and MEK kinases is still largely undefined. In this study, we portrayed in detail the somatic alterations of resistant melanoma and explored the associated biological processes and their integration with transcriptional profiles. By targeted next-generation sequencing and whole-exome sequencing analyses, a list of 101 genes showing imbalance in metastatic tumors from patients with a complete/durable response or disease progression during therapy with vemurafenib or with dabrafenib and trametinib was defined. Classification of altered genes in functional categories indicated that the mutational pattern of both resistant tumors and melanoma cell lines was enriched in gene families involved in oncogenic signaling pathways and in DNA repair. Integration of genomic and transcriptomic features showed that the enrichment of mutations in gene sets associated with anabolic processes, chromatin alterations, and IFN-α response determined a significant positive modulation of the same gene signatures at the transcriptional level. In particular, MTORC1 signaling was enriched in tumors from poorly responsive patients and in resistant tumors excised from treated patients. Results indicate that genetic patterns are associated with melanoma resistance to targeted therapy and disclose the underlying key molecular pathways to define drug combinations for improved personalized therapies. The genetic landscape of melanoma resistance to targeted therapy with small molecules inhibiting BRAF and MEK kinases is still largely undefined. In this study, we portrayed in detail the somatic alterations of resistant melanoma and explored the associated biological processes and their integration with transcriptional profiles. By targeted next-generation sequencing and whole-exome sequencing analyses, a list of 101 genes showing imbalance in metastatic tumors from patients with a complete/durable response or disease progression during therapy with vemurafenib or with dabrafenib and trametinib was defined. Classification of altered genes in functional categories indicated that the mutational pattern of both resistant tumors and melanoma cell lines was enriched in gene families involved in oncogenic signaling pathways and in DNA repair. Integration of genomic and transcriptomic features showed that the enrichment of mutations in gene sets associated with anabolic processes, chromatin alterations, and IFN-α response determined a significant positive modulation of the same gene signatures at the transcriptional level. In particular, MTORC1 signaling was enriched in tumors from poorly responsive patients and in resistant tumors excised from treated patients. Results indicate that genetic patterns are associated with melanoma resistance to targeted therapy and disclose the underlying key molecular pathways to define drug combinations for improved personalized therapies." @default.
• W4281567257 created "2022-05-27" @default.
• W4281567257 creator A5000391768 @default.
• W4281567257 creator A5005828835 @default.
• W4281567257 creator A5006090996 @default.
• W4281567257 creator A5010969749 @default.
• W4281567257 creator A5012265647 @default.
• W4281567257 creator A5027729250 @default.
• W4281567257 creator A5032506137 @default.
• W4281567257 creator A5039806537 @default.
• W4281567257 creator A5043915495 @default.
• W4281567257 creator A5046881872 @default.
• W4281567257 creator A5048439038 @default.
• W4281567257 creator A5053204150 @default.
• W4281567257 creator A5054198366 @default.
• W4281567257 creator A5061225830 @default.
• W4281567257 creator A5063636724 @default.
• W4281567257 creator A5066627217 @default.
• W4281567257 creator A5069765350 @default.
• W4281567257 creator A5074436993 @default.
• W4281567257 creator A5079904438 @default.
• W4281567257 creator A5082780385 @default.
• W4281567257 creator A5087113555 @default.
• W4281567257 creator A5088436342 @default.
• W4281567257 date "2022-11-01" @default.
• W4281567257 modified "2023-10-01" @default.
• W4281567257 title "Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles" @default.
• W4281567257 cites W1834835434 @default.
• W4281567257 cites W1950829641 @default.
• W4281567257 cites W1976078521 @default.
• W4281567257 cites W2035863659 @default.
• W4281567257 cites W2108537717 @default.
• W4281567257 cites W2111404068 @default.
• W4281567257 cites W2114903025 @default.
• W4281567257 cites W2116978375 @default.
• W4281567257 cites W2130410032 @default.
• W4281567257 cites W2133465414 @default.
• W4281567257 cites W2134471382 @default.
• W4281567257 cites W2137526110 @default.
• W4281567257 cites W2152061559 @default.
• W4281567257 cites W2158416296 @default.
• W4281567257 cites W2160766792 @default.
• W4281567257 cites W2275130777 @default.
• W4281567257 cites W2276335691 @default.
• W4281567257 cites W2518470597 @default.
• W4281567257 cites W2611187032 @default.
• W4281567257 cites W2735863468 @default.
• W4281567257 cites W2742903812 @default.
• W4281567257 cites W2795681258 @default.
• W4281567257 cites W2796153225 @default.
• W4281567257 cites W2885140428 @default.
• W4281567257 cites W2890488500 @default.
• W4281567257 cites W2896872272 @default.
• W4281567257 cites W2901242178 @default.
• W4281567257 cites W2908357079 @default.
• W4281567257 cites W2919111067 @default.
• W4281567257 cites W2950011075 @default.
• W4281567257 cites W2968171383 @default.
• W4281567257 cites W2989280842 @default.
• W4281567257 cites W2990997382 @default.
• W4281567257 cites W3000984240 @default.
• W4281567257 cites W3004219326 @default.
• W4281567257 cites W3005054303 @default.
• W4281567257 cites W3015729169 @default.
• W4281567257 cites W3023967107 @default.
• W4281567257 cites W3029985705 @default.
• W4281567257 cites W3031004830 @default.
• W4281567257 cites W3047167325 @default.
• W4281567257 cites W3084492169 @default.
• W4281567257 cites W3087046161 @default.
• W4281567257 cites W3087381804 @default.
• W4281567257 cites W3116507528 @default.
• W4281567257 cites W3183839551 @default.
• W4281567257 cites W3201405708 @default.
• W4281567257 doi "https://doi.org/10.1016/j.jid.2022.04.027" @default.
• W4281567257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35643181" @default.
• W4281567257 hasPublicationYear "2022" @default.
• W4281567257 type Work @default.
• W4281567257 citedByCount "3" @default.
• W4281567257 countsByYear W42815672572022 @default.
• W4281567257 countsByYear W42815672572023 @default.
• W4281567257 crossrefType "journal-article" @default.
• W4281567257 hasAuthorship W4281567257A5000391768 @default.
• W4281567257 hasAuthorship W4281567257A5005828835 @default.
• W4281567257 hasAuthorship W4281567257A5006090996 @default.
• W4281567257 hasAuthorship W4281567257A5010969749 @default.
• W4281567257 hasAuthorship W4281567257A5012265647 @default.
• W4281567257 hasAuthorship W4281567257A5027729250 @default.
• W4281567257 hasAuthorship W4281567257A5032506137 @default.
• W4281567257 hasAuthorship W4281567257A5039806537 @default.
• W4281567257 hasAuthorship W4281567257A5043915495 @default.
• W4281567257 hasAuthorship W4281567257A5046881872 @default.
• W4281567257 hasAuthorship W4281567257A5048439038 @default.
• W4281567257 hasAuthorship W4281567257A5053204150 @default.
• W4281567257 hasAuthorship W4281567257A5054198366 @default.
• W4281567257 hasAuthorship W4281567257A5061225830 @default.
• W4281567257 hasAuthorship W4281567257A5063636724 @default.
• W4281567257 hasAuthorship W4281567257A5066627217 @default.

• next